The U.S. Food and Drug Administration has authorized the first over-the-counter home test capable of simultaneously detecting respiratory syncytial virus (RSV), influenza A and B, and COVID-19 in adults and children as young as six months.
The Flowflex Plus 4-in-1 Home Test from ACON Laboratories allows caregivers to collect a nasal swab safely at home, delivering results within minutes without the need for laboratory processing.
RSV is a leading cause of hospitalization among young children, yet until now, no at-home test had been cleared for infants. By including RSV in its panel, the Flowflex Plus test fills a critical gap in early detection of respiratory infections that often present with similar symptoms such as fever, cough, congestion, and wheezing. Early identification can inform home monitoring, prompt medical care, and preventive measures for vulnerable household members.
The test is designed for use by parents or caregivers and employs a proprietary swab guard for safe sample collection in infants. Rapid at-home results allow families to differentiate among common viral infections, supporting more timely and informed healthcare decisions during peak respiratory virus seasons. The test is now available nationwide at major retail pharmacies, including CVS, Walgreens, and Albertsons, without a prescription.
The approval underscores a growing trend toward decentralized diagnostics, enabling families to obtain reliable health information outside traditional clinical settings. Home-based multiplex testing is increasingly recognized as a tool to reduce strain on healthcare facilities while promoting proactive management of respiratory illnesses.
